│Home│Sitemap│Notes for Usage│Inquiry│日本語│

2002 ■ The company was established on July 15, 2002 with Yen 10 million in capital.  Its mission is to market improved medical applications for DDS (drug delivery system) useful in colonic cancer treatment regimens incorporating Oxaliplatin, which are first-line drugs in Europe and the United States. Founding members include Professor Eriguchi and Associate Professor Yanagie of Research Center for Advanced Science and Technology Incubation Project : Cancer Metastasis, Department of Intellectual Property the University of Tokyo, Professor Maruyama, a DDS specialist Teikyo University School of Pharmaceutical Sciences, and Mr. Fujisawa, formerly in charge of marketing at a foreign pharmaceutical company. 　 2003 ■  Raised 1st round finance of Yen 20Mil in July ■  Raised 2nd round finance of Yen 10.5Mil in September ■  Raised 3rd round finance of Yen 200.2Mil in November 2004 ■ 　 Founded Research and Development Agreement with Mochida Pharmaceutical Co., Ltd ■ Awarded five-years “Development MB-324” Yen 56Mil/year from Pharmaceuticals and Medical Devices Agency ■ Awarded a year from Employment and Human Resources Development Organization, Tokyo Center　 ■ Raised 4th round finance of Yen 10Mil in June ■ Raised 5th round finance of Yen 1,003.14Mil in August ■ Japan -U.S. branch office established. (through JETRO project) 　 2005 ■ 　 Presentation at AACR “Pre-Clinical Study for Transferrin-modified PEG liposome containing Oxaliplatin” 　 2006 ■  Raised 6th round finance of Yen 1,525.11Mil in January ■  Raised 7th round finance of Yen 145Mil in March 2007 ■ Raised 8th round finance of Yen 600.9Mil in March ■ Presentation at American Association for Cancer Research (AACR) Annual Meeting 2007 in Los Angeles ◆MBP-426 ◆MBP-Y003 ■ Raised 9th round finance of Yen 357.9Mil in April 2010 ■ Raised 10th round finance of Yen 300.3Mil in August